TomP1: Wall St doesn’t seem very impressed right now with Missling or AVXL. The announcement of the LONG awaited ALZ Phase 2b/3 trial (now starting in Australia = WOW) has lost its luster. So far this morning, it is down another .16 (5%) to $3.30 and is dropping like a rock. My re-entry price of $2.25 is looking better every day. Whatever happened to this getting started here in the USA with the “NEW & IMPROVED FDA” and the highly touted Precision Medicine approach? Bottom line, by the time all 450 patients are enrolled (minimum 3-4 months) and the 48 week trial is officially over and done with, we are looking at at least 16 months from now before we will know any results. That’s October 2019 at the VERY EARLIEST. The MMs are going to have a heyday manipulating this stock over the next year and a half. Yikes.
Market Data 
Markets 
AI
